News
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
News
Patients with diabetes more likely to be hospitalized, especially with foot infection
August 9, 2021
Participants with diabetes faced a 67% increased risk of infection-related hospitalization, compared with those without diabetes.
![1]()
News
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.
![1]()
News
Unmanaged diabetes, high blood glucose tied to COVID-19 severity
June 26, 2021
Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes or A1c value.
![1]()
News
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
June 23, 2021
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
News
More obese, diabetic, chronically ill kids hospitalized with COVID-19
June 16, 2021
Children with diabetes, obesity, and cardiac and circulatory congenital anomalies were more likely to be hospitalized with COVID-19 and to be severely ill while hospitalized, a new study finds.
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
![1]()
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
May 18, 2021
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.
![1]()
News
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
May 18, 2021
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close.
News
In-hospital glucose management program gives dramatic savings
May 10, 2021
“I’ve been advocating for endocrine hospitalists to be deployed nationally,” said Dr. Misha Zilbermint.
